Tetrous announced expanded clinical use of its EnFix implants across multiple anatomical enthesis beyond rotator cuff repair. New applications include proximal/distal biceps tenodesis, insertional Achilles tendinopathy, gluteus medius and proximal hamstring reattachment, lateral epicondyle repair and subscapularis repair during total shoulder arthroplasty.
Driven by high failure rates in bone-to-tendon repair and increasing recognition of the enthesis as a critical biomechanical interface, these expanded indications are projected to increase the total addressable market for EnFix to almost $2 billion in the U.S. alone. EnFix TAC and EnFix RC are currently in clinical use in the United States, Australia and New Zealand, with global expansion underway.
Tetrous continues to collect clinical data across a broad range of orthopedic procedures and will provide updates as evidence develops. The EnFix implant is engineered to integrate seamlessly into existing techniques, offering biologic reinforcement with minimal surgical disruption.
Tetrous announced expanded clinical use of its EnFix implants across multiple anatomical enthesis beyond rotator cuff repair. New applications include proximal/distal biceps tenodesis, insertional Achilles tendinopathy, gluteus medius and proximal hamstring reattachment, lateral epicondyle repair and subscapularis repair during total shoulder...
Tetrous announced expanded clinical use of its EnFix implants across multiple anatomical enthesis beyond rotator cuff repair. New applications include proximal/distal biceps tenodesis, insertional Achilles tendinopathy, gluteus medius and proximal hamstring reattachment, lateral epicondyle repair and subscapularis repair during total shoulder arthroplasty.
Driven by high failure rates in bone-to-tendon repair and increasing recognition of the enthesis as a critical biomechanical interface, these expanded indications are projected to increase the total addressable market for EnFix to almost $2 billion in the U.S. alone. EnFix TAC and EnFix RC are currently in clinical use in the United States, Australia and New Zealand, with global expansion underway.
Tetrous continues to collect clinical data across a broad range of orthopedic procedures and will provide updates as evidence develops. The EnFix implant is engineered to integrate seamlessly into existing techniques, offering biologic reinforcement with minimal surgical disruption.
Copy to clipboard 
